{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:08:38Z","timestamp":1793981318475,"version":"4.8.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This meta-analysis aims to evaluate the effect of semaglutide, a glucagon-like peptide-1 receptor agonist, on new-onset atrial fibrillation (AF) in randomized clinical trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Twenty-six RCTs involving 48 583 participants (of whom 25 879 on semaglutide) with 541 new-onset AF were analyzed. Semaglutide treatment resulted in a 17% reduction in AF incidence compared to controls (odds ratio [OR] 0.83, 95% confidence interval [CI] 0.70\u20130.98, P = 0.03) with no heterogeneity (I\u00b2 = 0%). The effect was more pronounced with the oral formulation, which reduced AF incidence by 52% (OR 0.48, 95% CI 0.24\u20130.95, P = 0.04), while studies with active comparators showed a 59% reduction in AF risk (OR 0.41, 95% CI 0.20\u20130.83, P = 0.01). In trials without sodium-glucose co-transporter 2 inhibitors (SGLT2i) concomitant therapy, there was a significant reduction of 21% in new-onset AF (OR 0.79, 95% CI, 0.63\u20130.99; P = 0.04). Meta-regression revealed no influence of baseline covariates, including BMI and HbA1c. An additional meta-regression analysis evaluating the percentage of patients on SGLT2 inhibitors as a potential moderator revealed no statistically significant association (P = 0.336).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with semaglutide significantly reduces the incidence of new-onset AF. This effect appears more evident with the oral formulation and independent of baseline characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf257","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T14:20:23Z","timestamp":1745850023000},"source":"Crossref","is-referenced-by-count":45,"title":["Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-1235","authenticated-orcid":false,"given":"Arturo","family":"Cesaro","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , VIa L. Bianchi, Naples 80131 ,","place":["Italy"]},{"name":"Division of Cardiology, A.O.R.N. \u2018Sant'Anna e San Sebastiano\u2019 , Via Palasciano, Caserta 81100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal, Anesthesiological, and Cardiovascular Sciences, Sapienza University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1196-7582","authenticated-orcid":false,"given":"Vincenzo","family":"Acerbo","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , VIa L. Bianchi, Naples 80131 ,","place":["Italy"]},{"name":"Division of Cardiology, A.O.R.N. \u2018Sant'Anna e San Sebastiano\u2019 , Via Palasciano, Caserta 81100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-6596","authenticated-orcid":false,"given":"Flavio Giuseppe","family":"Biccir\u00e8","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, San Giovanni-Addolorata Hospital , Rome ,","place":["Italy"]},{"name":"Department of General and Specialized Surgery \u2018Paride Stefanini\u2019, Sapienza University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0141-0127","authenticated-orcid":false,"given":"Michele","family":"Golino","sequence":"additional","affiliation":[{"name":"Pauley Heart Center, Virginia Commonwealth University , Richmond, VA ,","place":["USA"]},{"name":"Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Panico","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , VIa L. Bianchi, Naples 80131 ,","place":["Italy"]},{"name":"Division of Cardiology, A.O.R.N. \u2018Sant'Anna e San Sebastiano\u2019 , Via Palasciano, Caserta 81100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-2030","authenticated-orcid":false,"given":"Francesco","family":"Prati","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, San Giovanni-Addolorata Hospital , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-785X","authenticated-orcid":false,"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[{"name":"Pauley Heart Center, Virginia Commonwealth University , Richmond, VA ,","place":["USA"]},{"name":"Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University & Liverpool Heart and Chest Hospital , Liverpool ,","place":["UK"]},{"name":"Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University , Aalborg ,","place":["Denmark"]},{"name":"Department of Cardiology, Lipidology and Internal Medicine with Intensive Coronary Care Unit, Medical University of Bialystok , Bialystok ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , VIa L. Bianchi, Naples 80131 ,","place":["Italy"]},{"name":"Division of Cardiology, A.O.R.N. \u2018Sant'Anna e San Sebastiano\u2019 , Via Palasciano, Caserta 81100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2025050806122504200_zwaf257-B1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","article-title":"Atrial fibrillation and diabetes Mellitus: JACC review topic of the week","volume":"74","author":"Wang","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025050806122504200_zwaf257-B2","doi-asserted-by":"crossref","first-page":"e032277","DOI":"10.1161\/JAHA.123.032277","article-title":"Impact of obesity on atrial fibrillation pathogenesis and treatment options","volume":"13","author":"Sha","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025050806122504200_zwaf257-B3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejim.2022.04.026","article-title":"Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF long-term general registry","volume":"103","author":"Ding","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2025050806122504200_zwaf257-B4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacep.2015.04.004","article-title":"Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation","volume":"1","author":"Wong","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"2025050806122504200_zwaf257-B5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","article-title":"Targeting the incretin system in obesity and type 2 diabetes mellitus","volume":"20","author":"Ansari","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2025050806122504200_zwaf257-B6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"2025050806122504200_zwaf257-B7","doi-asserted-by":"crossref","first-page":"1379189","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2025050806122504200_zwaf257-B8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13098-022-00970-2","article-title":"Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Wu","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"2025050806122504200_zwaf257-B9","doi-asserted-by":"crossref","first-page":"e14292","DOI":"10.1111\/eci.14292","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis","volume":"54","author":"Saglietto","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2025050806122504200_zwaf257-B10","first-page":"101218","article-title":"Effects of GLP-1 agonists on mortality and arrhythmias in patients with type II diabetes","volume":"47","author":"Al-Sadawi","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2025050806122504200_zwaf257-B11","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.numecd.2020.03.013","article-title":"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"30","author":"Nreu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025050806122504200_zwaf257-B12","doi-asserted-by":"crossref","first-page":"103067","DOI":"10.1016\/j.dsx.2024.103067","article-title":"Semaglutide for the prevention of atrial fibrillation: a systematic review and meta-analysis","volume":"18","author":"Zhang","year":"2024","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2025050806122504200_zwaf257-B13","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2025050806122504200_zwaf257-B14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025050806122504200_zwaf257-B15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025050806122504200_zwaf257-B16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025050806122504200_zwaf257-B17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"2025050806122504200_zwaf257-B18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025050806122504200_zwaf257-B19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/dom.13218","article-title":"Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025050806122504200_zwaf257-B20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2025050806122504200_zwaf257-B21","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"2025050806122504200_zwaf257-B22","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2025050806122504200_zwaf257-B23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"The Lancet"},{"key":"2025050806122504200_zwaf257-B24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025050806122504200_zwaf257-B25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025050806122504200_zwaf257-B26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2025050806122504200_zwaf257-B27","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/dom.14232","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025050806122504200_zwaf257-B28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2025050806122504200_zwaf257-B29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74\u2005mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"The Lancet"},{"key":"2025050806122504200_zwaf257-B30","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2025050806122504200_zwaf257-B31","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025050806122504200_zwaf257-B32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025050806122504200_zwaf257-B33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"2025050806122504200_zwaf257-B34","doi-asserted-by":"crossref","first-page":"e003206","DOI":"10.1136\/bmjdrc-2022-003206","article-title":"Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial","volume":"11","author":"Buse","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025050806122504200_zwaf257-B35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2025050806122504200_zwaf257-B36","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025050806122504200_zwaf257-B37","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2025050806122504200_zwaf257-B38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025050806122504200_zwaf257-B39","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","article-title":"Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, phase IIIa, randomised trial","volume":"67","author":"Wang","year":"2024","journal-title":"Diabetologia"},{"key":"2025050806122504200_zwaf257-B40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74\u2005mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025050806122504200_zwaf257-B41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/oby.2002.104","article-title":"Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity","volume":"10","author":"Iacobellis","year":"2002","journal-title":"Obes Res"},{"key":"2025050806122504200_zwaf257-B42","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025050806122504200_zwaf257-B43","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","article-title":"Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025050806122504200_zwaf257-B44","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025050806122504200_zwaf257-B45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurjpc\/zwad300","article-title":"Five-year changes in weight and risk of atrial fibrillation in the danish diet, cancer, and health cohort","volume":"31","author":"Frederiksen","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025050806122504200_zwaf257-B46","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.amjcard.2014.07.045","article-title":"Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes Mellitus (from the action to control cardiovascular risk in diabetes study)","volume":"114","author":"Fatemi","year":"2014","journal-title":"Am J Cardiol"},{"key":"2025050806122504200_zwaf257-B47","first-page":"410","article-title":"Impact of long-term glycemic variability on development of atrial fibrillation in type 2 diabetic patients","volume":"18","author":"Gu","year":"2017","journal-title":"Anatol J Cardiol"},{"key":"2025050806122504200_zwaf257-B48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-021-01341-3","article-title":"Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus","volume":"20","author":"Hsu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025050806122504200_zwaf257-B49","doi-asserted-by":"crossref","first-page":"1126581","DOI":"10.3389\/fendo.2023.1126581","article-title":"Glycemic variability and the risk of atrial fibrillation: a meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025050806122504200_zwaf257-B50","doi-asserted-by":"crossref","first-page":"e022222","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025050806122504200_zwaf257-B51","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf257\/63023508\/zwaf257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf257\/63023508\/zwaf257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:12:38Z","timestamp":1746684758000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwaf257\/8121325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf257","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"zwaf257"}}